Old Articles: <Older 7751-7760 Newer> |
|
The Motley Fool August 4, 2011 Frank Vinluan |
Skin in the Game: How Acne Skin Care Fits GSK's Drug Portfolio Strategy GSK thinks long-term with this acne skin care product. |
The Motley Fool August 3, 2011 Rex Moore |
Let's See If Mindray Medical's Growth Is for Real Mindray's tangible book value is $748.7 million, so no yellow flags here. |
The Motley Fool August 3, 2011 Brian Orelli |
Ignore Pfizer's Financials for Now It's the pipeline that matters. |
Chemistry World August 3, 2011 Patrick Walter |
Merck Continues Restructuring and Cuts 13,000 Jobs US drug giant Merck & Co will lay off as much as 13 per cent of its workforce - up to 13,000 staff - by the end of 2015. The move is part of an aggressive cost cutting drive to streamline the company. |
The Motley Fool August 3, 2011 Brian Orelli |
Arena Sheds a Few Pounds Off Its To-Do List The brain cancer issue seems to be rat specific. |
The Motley Fool August 1, 2011 Anders Bylund |
Universal Health Services Shares Plunged: What You Need to Know Shares of hospital and care center operator Universal Health Services are taking a sick day today after falling as much as 10.9% on heavy volume. |
The Motley Fool August 1, 2011 Brian Orelli |
Bravo? Not Really. Teva's oral multiple sclerosis drug, laquinimod, fails to impress. |
The Motley Fool August 1, 2011 Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Alphatec Holdings Alphatec Holdings seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
The Motley Fool August 1, 2011 Rex Moore |
Let's See If CareFusion's Growth Is for Real Here are two simple metrics than can save you from a lot of pain. |
The Motley Fool July 29, 2011 Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
<Older 7751-7760 Newer> Return to current articles. |